


# 1<sup>st</sup> Alumni Refresher Vaccinology Course (6-8 June + 13-15 June 2023)

## List of Lecturers

**Dr Edwin Asturias** is paediatric infectious diseases doctor with a public health background who is currently working as Associate Director for the Centre for Global Health at the University of Colorado Anschutz Medical Campus. He was boarded in paediatrics at University of Colorado Health Sciences Centre in 1995 and Paediatric Infectious Diseases at the Johns Hopkins School of Medicine in 1998. He has led for 25 years clinical trials, implementation research and policy for introduction and safety of vaccines for children in low- and middle-income countries including Hib, pneumococcus, poliovirus, dengue, influenza, and novel coronavirus. Dr. Asturias founded and has served on the Guatemalan National Committee for Immunization Practices, the Poliovirus Contention Commission, and advisory groups for the World Health Organization, including the Global Advisory Committee on Vaccine Safety. He is now the coordinator for the Advance Vaccinology Course of the University of Geneva and Foundation Merieux in France and member of the World Health Organization Expert Advisory Group for the Malaria Vaccine. In 2020, he served his native country, Guatemala as the Presidential Commissioner for the Emergency of COVID-19. He is now leading studies on evaluating the impact of influenza and COVID-19 in agricultural workers and households, new methods for diagnosis of pneumonia and measuring the impact of novel pneumococcal vaccines and elucidating transfer of RSV maternal antibodies in anticipation of upcoming RSV vaccines. He is the member of ACIP working groups on polio and dengue in the United States and an active member on immunizations for the PAHO/WHO Collaborating Centre for Family and Child Health based at the University of Colorado.



**Prof. Isabelle Bekeredjian-Ding** is Head of the Microbiology Division and acting director of the Center for Pandemic Vaccines and Therapeutics (ZEPAI) at Paul-Ehrlich-Institut (PEI). She is an Associate Professor at the University of Bonn and holds a clinical specialization in Medical Microbiology, Virology and Epidemiology of Infection, and a research track record in immunology. Prof. Bekeredjian-Ding received Medical School training at the Universities of Heidelberg, Padua (Italy) and Mt. Sinai, New York, as well as clinical training in Munich and Heidelberg. Before joining PEI, she was deputy director of the Institute of Medical Microbiology, Immunology and Parasitology in Bonn. Prof. Bekeredjian-Ding served as a Member at the EMA CHMP Vaccines Working Party and as Chair of the Scientific Committee of the IMI2 JU program, among other offices.

**Cristina Casetti** is the Deputy Director of the Division of Microbiology and Infectious Diseases (DMID) at the National Institutes of Allergy and Infectious Diseases (NIAID), a component of the US National Institutes of Health (NIH). Dr. Casetti has a Ph.D. in virology from the University of Rome, Italy. She has conducted research on poxviruses replication at the NIH, influenza virus biology at Rutgers University and HPV vaccine development at the Vaccine Discovery Department at Wyeth (now Pfizer). In 2003 she became a Program Officer at NIAID where she was responsible for the management and direction of extramural research programs on several emerging viral diseases of global health importance including influenza and dengue. In 2016, she was appointed to coordinate the Zika research response in extramural NIAID and to manage translational research in the Virology Branch. In 2017 she was appointed as Chief of the Virology Branch in DMID. In 2019 she became the Deputy Director of DMID where she shares responsibilities with the director for the overall scientific direction, administration and management of the largest extramural Division at NIAID.



**Dr. Alejandro Cravioto** is currently a professor at the Faculty of Medicine of the National Autonomous University of Mexico in Mexico City. Dr. Cravioto served as Dean of the Faculty from and as Executive Director of the International Centre for Diarrhoeal Disease Research (icddr,b) in Dhaka, Bangladesh. He has served as Chief Scientific Officer of the International Vaccine Institute (IVI) in Seoul, Republic of Korea. Dr. Cravioto received his Medical Degree with honors from the Faculty of Medicine of UNAM. He specialized in Pediatrics at the National Institute of Pediatrics in Mexico City, followed by training at the London School of Hygiene and Tropical Medicine of the University of London, where he received a Diploma in Tropical Public Health and a Ph.D. He served as the Chair of the Strategic Advisory Group of Experts (SAGE) on Immunization of the World Health Organization from 2015 to 2022, and is currently a member of the advisory group for the Gavi Vaccine Investment Strategy 2024.

**Dr Clare Cutland** is the Scientific Coordinator of the African Leadership in Vaccinology Expertise (Alive) consortium, which is led by co-directors Professors Helen Rees (Wits RHI) and Shabir Madhi (Wits-VIDA). Previously, she spent 18 years as a clinical researcher in vaccinology at the Respiratory and Meningeal Pathogens Research Unit (RMPRU, now Wits-VIDA), based at Chris Hani Baragwanath Academic Hospital (CHBAH), Soweto, South Africa. She was an investigator on numerous phase I, II and III paediatric, maternal and COVID-19 clinical vaccine trials, and was the clinical lead for several large grant-funded neonatal sepsis prevention studies, maternal-neonatal sepsis surveillance studies and maternal immunization trials (Influenza, GBS, RSV). She was involved in the GAIA Brighton collaboration definition working groups (2014-2020), and was elected as a member of the scientific board of the Brighton collaboration in 2018 (to present). She is a member of the Wits Institutional biosafety committee and working group for maternal COVID-19 vaccines. She coordinates a biennial 9-day short course in vaccinology (Afro-ADVAC) and a Masters of Science (Med) in the field of vaccinology at The University of the Witwatersrand. She is author or co-author on over 120 peer-reviewed journal articles.





**Niklas Danielsson** studied medicine at the Karolinska Institute in Stockholm and trained in pediatrics at Astrid Lindgren's Children's hospital. He practiced clinical medicine in Zambia early in his professional life before pursuing a career in international child health, immunization, and epidemiology. He contributed to the development of the Integrated Management of Childhood Illness (IMCI) and has held senior positions at WHO and ECDC. Since 2016, he works for UNICEF as Senior Immunization Specialist where his focus is on improving coverage and equity, and reaching zero-dose children and underserved communities in low income countries with vaccines and other primary health care (PHC) services. He contributed to the development of Immunization Agenda 2030 and co-chairs the working group on Coverage and Equity in immunization. He serves on the UNICEF secretariat for the Equity Reference Group for Immunization (ERG), an action-oriented think-tank of senior global health experts from WHO, GAVI, WB, BMGF, UNICEF and academia that is concerned with improving equity in immunization. He is an ADVAC alumni, has a MSc degree in epidemiology from LSHTM, and he is passionate about accelerating deployment and scale-up of innovations, digital and others, for reaching the world's most vulnerable and marginalized children.

**Adrien de Chaisemartin** is the Deputy Director for Gavi, Immunization Partners, and Special Initiatives at the Bill & Melinda Gates Foundation. Adrien joined the Foundation in August 2021 where he initially led the work on Covid vaccine supply during the Covid Pandemic. Previous to joining the Foundation, Adrien was serving as the Director for Strategy Funding & Performance at Gavi, where he coordinated the design of Gavi 4.0 and 5.0 strategies and led the transformation of Gavi's engagement model with partner institutions. Before joining Gavi in 2011, Adrien worked at McKinsey & Company in Johannesburg, South Africa. For 6 years he worked on public health projects, including on MNCH strategies in Ethiopia, HIV in Botswana, climate change and health in Tanzania and other economic development projects in Kenya and South Africa. Adrien holds a Master of Science from Ecole Polytechnique, France, a Master of Applied Mathematics from Harvard University, and a Master of Public Health from Johns Hopkins University.



**Arnaud Didierlaurent** was trained as an engineer in Biotechnology in France. After gaining his Master's degree at the University of Washington (Steve Ziegler's lab) in 1999, Arnaud obtained his PhD in cellular immunology from the University of Lausanne in 2003 at ISREC under the supervision of Jean-Pierre Kraehenbuhl and Jean-Claude Sirard. Arnaud continued his work on innate immunity in the lab of Jürg Tschopp before joining the Imperial college, London, where he worked as postdoctoral fellow from 2004 to 2007 on the long-term impact of viral infection on the lungs. In 2006, he was awarded a prize from the Novartis Foundation as a research fellow in Ralph Steinman's lab at the Rockefeller University in New York. Arnaud then joined the R&D department of GlaxoSmithKline in 2008 in Belgium, where he held several leading positions in vaccine research and development. Initially head of a lab investigating the mode of action of adjuvant, Arnaud became in charge of the GSK Adjuvant System portfolio and thus directly involved in the licensure of several adjuvanted vaccines. Arnaud's scientific

contributions have consequently been focused on deciphering the interplay between innate immunity and pathogen/vaccine-specific adaptive response. Before joining the University, he was global medical affairs director and responsible for the launch of the GSK Zoster vaccine in Japan and European markets, which further increased his understanding of implementation of vaccine programs. With his experience in both academic and industrial settings, Arnaud has acquired a deep understanding of how vaccines are created, developed, and deployed. He joined the Center of vaccinology in March 2020 to continue his work on translational vaccine research as Assistant Professor. He was recently appointed by WHO as chairman of the Technical Advisory Group who provides recommendations for the Emergency Use listing of COVID-19 vaccine candidates. Since February 2023, he is the director of the Center of Vaccinology at the Faculty of Medicine in Geneva and responsible of ADVAC for the University of Geneva"

**Janet Englund, MD**, is Professor of Pediatric Infectious Diseases at the University of Washington School of Medicine and Seattle Children's Hospital. She studies new viruses, viral vaccines and novel agents for the treatment and prevention of respiratory viruses including influenza, respiratory syncytial virus (RSV), and SARS-CoV-2 (COVID-19). She has studied maternal immunization to protect mothers and infants against pertussis, influenza, and respiratory syncytial virus. Dr. Englund's research group at Seattle Children's Hospital is part of the New Vaccine Surveillance Network of the Centers for Disease Control (2010-2021), participating in respiratory and gastrointestinal viral surveillance in King County. This group assesses vaccine effectiveness in population-based studies of healthy children. She also is a leader of the Seattle Flu Study, a group of investigators who evaluate the spread of respiratory viruses within the community and helped identify the first case of community COVID-19 in the USA. Her group evaluates new methods to diagnose and characterize viral respiratory diseases, including COVID-19. Dr. Englund has been active in national and international organizations including American Academy of Pediatrics, the CDC-sponsored Advisory Committee on Immunization Practices (ACIP), the FDA Vaccines and Related Biological Products Advisory Committee (VRPBAC), and the Maternal Immunization Safety Group at the World Health Organization (WHO). She is past president of the Pediatric Infectious Disease Society, past member of the WHO Influenza working group and the Board of Directors of the Infectious Disease Society of America (IDSA), and a current member of the IDSA COVID-19 Diagnosis Working Group.



**Dr Mary Hamel** is a Senior Technical Officer in the Department of Immunization, Vaccines & Biologicals, at the World Health Organization. She is the Team Lead for the Malaria Vaccines Team and leads the RTS,S Malaria Vaccine Implementation Programme, which supports pilot implementation of the first malaria vaccine in Malawi, Kenya and Ghana. She is a medical epidemiologist with over 26 years of experience in malaria and child health research and public health. She is a medical doctor, with a specialty in internal medicine, subspecialty in infectious diseases and a diploma in Tropical Medicine and Hygiene. Dr Hamel has led and supervised numerous malaria-related studies, primarily in Africa, focusing

on malaria in children, pregnant women, and HIV infected persons and transmission reduction efforts. Prior to joining WHO, she was the Deputy Chief for Science and Chief of the Strategic and Applied Science Unit for the Malaria Branch, U.S. Centers for Disease Control and Prevention (CDC). She served as the Malaria Branch Chief at KEMRI/CDC Research and Public Health Collaboration, located in

Kisumu, in western Kenya from 2004 – 2010, where she served on a number of Kenya National Malaria Control Working Groups. She was the Senior Technical Advisor to the President's Malaria Initiative in Washington DC from 2010 – 2014. She lives in Switzerland with her husband and two teenage children.

**Dr Joachim Hombach** is Senior Health Adviser and Executive Secretary of WHO's principal advisory body on immunization SAGE at the Department of Immunisation, Vaccines and Biologicals of WHO. As head of the policy team, he provides leadership on the development of policies and strategies. His team also provides support to the development of capacity of national immunization technical advisory groups, and the implementation of policies through interaction with regional immunization technical advisory bodies. During the ongoing COVID-19 pandemic, his team has been leading the development of global COVID-19 vaccination recommendations. Joachim Hombach had several other managerial positions at WHO in the field of vaccine research and immunization. Before joining WHO, Joachim Hombach had positions with the global vaccine industry and the European Commission. Dr Hombach holds a PhD in immunology from the University of Cologne, Germany and an MPH from Johns Hopkins University, Baltimore, USA. Multiple peer-reviewed publications have emerged from his work in academia and global public health.



**Dr. Hector Izurieta** is currently Associate Director for Novel Clinical Investigations at the Office of Vaccine Research and Review (OVRR), CBER/FDA. Born in Uruguay, has an MD degree from South America, an MPH from Harvard University, a PhD in Epidemiology from Spain, a CDC Preventive Medicine fellowship and a two-year training in Epidemiology at CDC's Epidemic Intelligence Service (EIS).

He has extensive international experience in vaccine safety and effectiveness, and in the use of Real-world evidence. He has worked at:

1. FDA, in vaccine epidemiology, since 2003
2. CDC, in the EIS and Preventive Medicine programs (1993-6), influenza Division (1996-9), Pan-American Health Organization (PAHO/WHO) as CDC-seconded point person for measles elimination (goal achieved in 2003) and subsequently as acting Chief, Immunization Unit
3. WHO, under contract with the Gates Foundation, developing guidelines for national vaccination campaigns and supporting Measles vaccination campaigns in Tchad (2014-15).
4. Previously worked in South Sudan for 2 years in emergency medicine for Médecins Sans Frontières France, and in Benin, in a health development program, for an agency of the Swiss Cooperation for 3 years.

He has published close to 100 manuscripts on COVID-19, Influenza, Herpes Zoster, Measles, Tetanus, Diphtheria, Pertussis, other vaccine-preventable diseases, and on vaccine and RWE research methods.

**Philippe Juvin** is Chief Pharmaceutical officer and Associate Vice-President Global Product Quality Management, based at Sanofi Pasteur headquarter in Lyon since March 2013. Previously, Philippe was Quality Operations Senior Director and Chief Pharmaceutical Officer at Genzyme Polyclonals Lyon since March 2008. He started his career in the nineties and held different positions in production and quality departments of pharmaceutical companies (Genzyme Polyclonals, Solvay Pharmaceuticals, Aventis-Pharma, Boehringer Ingelheim, Roussel Diamant Ciba Geigy). In his mission as Quality Director, one of his main achievements was to bring Solvay Pharmaceuticals site based in the Lyon Region to the FDA cGMP agreement for two products in May 2007, then to prepare the new Genzyme Polyclonals biotech site to international approvals. Philippe Juvin is a Doctor in Pharmacy graduated from the Lyon Pharmacy University and he holds a master degree for Quality and Quality management from the Lyon Claude Bernard University.



**David C. Kaslow, MD**, is director of the Office of Vaccines Research and Review (OVRR), Center for Biologics Evaluation and Research (CBER), US Food and Drug Administration (US FDA). Prior to joining US FDA in October of 2022, David served as PATH's Chief Scientific Officer at PATH, supporting PATH's Drug Innovation and Access Initiative and heading PATH's Center for Vaccine Innovation and Access (CVIA). His 35+ years of experience in product development and introduction include the US government (NIH), biotech (Vical), multi-national pharma (Merck Research Laboratories), and non-profit (PATH) sectors. David served in the US Public Health Service at NIAID, and has served on a number of advisory committees, including WHO Product Development of Vaccines Advisory Committee (PDVAC). David

received a B.S. in biochemistry from University of California, Davis, and a M.D. from University of California, San Francisco.

**Dr. Ombeva Malande** is a Vaccinologist & a Paediatric infectious Diseases specialist. A certified fellow of the College of Paediatricians of South Africa, he is a Lecturer at Egerton University, an Honorary Lecturer at Makerere University, and a research associate at the Sefako Makgatho Health Sciences University, South Africa. He has consulted for WHO, UNICEF, MSD, Pfizer, GSK, Medscape, Sanofi Pasteur, Facebook, Merc, GIZ, Old Mutual, Minet, AON, Jubilee, Liberty Blue, Equity Bank, Standard Chartered Bank, Bank of Africa, USAID, Britam among others. He has participated as a technical advisor and consultant on several National and International Taskforces and technical working groups and developed guidelines and SOPs on Ebola, HIV, Malaria, Rota Virus Diarrhoea, influenza, Pneumonia, TB, and COVID-19. He is the Director of East Africa Centre for Vaccines and Immunization (ECAVI) and a convener of the widely acclaimed ECAVI vaccinology course for health professionals, and ECAVI Resource Mobilization Courses. He has authored two books, has over 30 peer-reviewed scientific papers, over 70 presentations in local and international scientific meetings, and is an editorial board member and reviewer for various scientific journals. He is a respected poet, who for over



20 years has written award-winning poems for drama and music festivals for primary and high school children in Kenya. He is a weekly Columnist and Advocate on Child Health with the Standard Media Group in Kenya.

**Anna-Carin Matterson** is a health systems and health policy specialist with over 20 years of experience in health policy design, development and review and in managing health programs at global, regional and country levels (including 14 years in-country in Zambia, Kenya, Uganda and Sudan). Anna-Carin first joined Gavi's Policy team in 2012 and has worked with the team in several policy development and review processes, including of Gavi's Gender policy, Fragility, Emergencies and Displaced populations policy, Risk policy, Transparency and Accountability policy and most recently in the review of Gavi's funding policies. She is currently supporting the Vaccine Investment Strategy. Anna-Carin holds a MSc in Health- and Pharmaco-Economics from UPF Barcelona and a Bachelor in Economics from Stockholm University.



**Dr Gustavo Mendes Lima Santos** is a pharmacist with a regulatory background who is currently working as Director of Regulatory, Quality and Clinical Trials at Fundação Butantan, a Brazilian governmental institution for vaccine manufacturing. He was previously Research Scientist in the Regulatory Affairs Office at International Vaccine Institute (IVI). He completed his PhD from University of Maringa in Pharmaceutical Sciences and worked more than 20 years as regulator in the Brazilian Health Regulatory Agency (Anvisa). His activities as regulator included GMP/GCP inspections and dossier reviewer of vaccines and medicines. He is the formal General Manager of Medicines and Biological Products at Anvisa, in charge of establishing Brazilian regulations during COVID-19 pandemic. He has published more than 30 research and review articles on regulatory science.

He was member of Product Development for Vaccines Advisory Committee, which is an independent standing WHO committee of experts which provides external advice to WHO related to priority infectious disease pathogens, associated vaccine and monoclonal antibody product development approaches and related manufacturing and delivery technologies.

**Denise Naniche** is Scientific Director at ISGlobal, Research professor and coordinator of the annual accredited Masters course "*Development and Applications of Vaccines in Global Health*" given as an independent course or in the Masters of Global Health. She earned her PhD in Immunology at the University of Lyon I, France and a Master in Public Health at San Diego State University in California. She is an internationally recognized researcher in clinical immunology and epidemiology of viral infections, particularly in Measles and HIV. Over the past 20 years, her broad background in applied immunology and clinical epidemiology have led her to conduct multidisciplinary research focused on improving access to HIV diagnosis, treatment and control in Sub-Saharan Africa. She developed the Vaccinology course at ISGlobal in 2014 and has coordinated it ever since. She has



mentored PhD and master's students and her team has worked closely with the Mozambican National HIV program to foster translation of results into policy. Since 2020, she has been an active member of the Lancet Commission for Covid-19 in the *Vaccines and Therapeutics* task force.



**Dr. Kathleen Neuzil** is the Myron M. Levine Professor in Vaccinology, Professor of Medicine and Pediatrics, and the Director of the Center for Vaccine Development and Global Health at the University of Maryland School of Medicine. She is an internationally recognized research scientist and advocate in the field of vaccinology. Throughout her career, Dr. Neuzil has conducted clinical and epidemiologic studies on vaccine-preventable diseases, yielding high-profile publications that inform policy decisions and public health actions. Dr. Neuzil's work has spanned dozens of low-resource countries with multiple vaccines, including influenza, rotavirus, human papillomavirus, Japanese encephalitis, typhoid conjugate vaccines, and most recently, COVID-19 vaccines. Dr. Neuzil was central to the domestic and global response to COVID-19. As a co-PI of the NIH-funded

Leadership Group for the Vaccine and Treatment Evaluation Unit network, Dr. Neuzil was part of the strategic team evaluating COVID vaccines and therapeutics in the US and was part of the study team who designed the first COVID-19 clinical vaccine trial in the US. Dr. Neuzil directs TyVAC, the Typhoid Vaccine Acceleration Consortium, with the goal to accelerate the introduction of typhoid conjugate vaccines into low-resource countries. She has more than 300 scientific publications on vaccines and infectious diseases, and is a member of the prestigious National Academy of Medicine. Dr. Neuzil's research capabilities are complemented by 20 years of involvement in domestic and international policy, including past membership on the US Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices. She is a member of the World Health Organization Strategic Advisory Group of Experts on Immunization.

In September 2022, **Aurélia Nguyen** was appointed Chief Programme Strategy Officer at Gavi, the Vaccine Alliance – the first person to hold the position. In this role, Aurélia provides strategic direction on Gavi's vaccine portfolio; ensures cohesion and coordination in implementing Gavi's current strategy and planning for the next strategic period; and incorporates key learnings into Gavi policies and programmes. Previously, Aurélia served as Managing Director of the Office of the COVAX Facility, beginning in October 2020. In this role, Aurélia led the coordination of procurement and delivery of COVID-19 vaccines to 146 countries through COVAX, the only global initiative that is working with governments and manufacturers to ensure COVID-19 vaccines are available worldwide to both high-income and lower-income countries. In a previous appointment, Aurélia served as Gavi's Managing Director for Vaccines & Sustainability, leading the end-to-end work of designing Gavi's vaccine programmes. She and her team were responsible for designing ways for Gavi's resources to support financially sustainable vaccine programmes and markets, and ultimately increase uptake of life-saving vaccines. Prior to joining Gavi in 2011, Aurélia held a variety of posts between 1999 and 2010 within GlaxoSmithKline, where latterly she led the development of GSK's policies on access to medicines and vaccines in lower-income countries. She has also undertaken research for the World Health Organization (WHO) on generic medicines policies. Aurélia is a certified accountant and holds a Master's degree in Health Policy, Planning & Financing from the London School





of Hygiene & Tropical Medicine and the London School of Economics. Aurélia was named by TIME magazine to the 2021 TIME100 Next list honouring "the 100 individuals who are shaping the future of their fields and defining the next generation of leadership".



Trained as an immunologist at the Pasteur Institute (Paris, France), **Prof. Steve Pascolo** used mouse models to test and develop mRNA-based vaccines (direct injection of mRNA) during his post-doc in Tuebingen, Germany from 1998 till 2000. In 2000, he co-founded CureVac with Dr. Hoerr and Dr. von der Mulbe. Dr. Pascolo was Chief Scientific Officer (CSO) of the company from 2000 till 2006, developing the technology, implementing the worldwide first GMP production of mRNA and in 2003 performing the worldwide first mRNA vaccine clinical studies where humans (including himself) got injections of in vitro transcribed mRNA. In 2006, he joined the oncology department of the University Hospital of Zurich, Switzerland and continued the development of immunotherapies based on RNA. In 2008, he founded Miescher Pharma to support this work. In 2017,

Dr. Pascolo implemented in Zurich an academic mRNA platform <https://www.cancer.uzh.ch/en/Research/mRNA-Platform.html> In collaboration with several research and clinical departments in Zurich he optimizes, tests and implements mRNA based vaccines and therapies.

**Brett W. Petersen** is a Commander in the United States Public Health Service and currently serves as the Deputy Branch Chief for CDC's Poxvirus and Rabies Branch. He began his career at CDC as an Epidemic Intelligence Service officer with the rabies team where he participated in multiple outbreak responses and field investigations involving rabies virus and other pathogens. Among other accomplishments, Dr. Petersen led the development of national recommendations for the use smallpox vaccine in an emergency as well as for laboratory workers as the lead for the Advisory Committee on Immunization Practice (ACIP) smallpox vaccine working group. He continues to participate in outbreak responses including leading a COVID19 Response Assistance Field Team in 2020, serving as the Deputy Incident Manager for CDC's response to Zika in 2016-2017, and deploying to Liberia to assist with the Ebola response in 2014. Prior to joining CDC, Dr. Petersen received his bachelors of science from the University of California, San Diego, his masters of public health from Johns Hopkins University, and his medical degree from the University of Michigan. He completed his medical training at the University of California San Diego Medical Center and is board certified in internal medicine.





**Dr Kamel Senouci** is the Director of the ADVAC course at the University of Geneva. He has more than 20 years of work in public health, with a strong experience in vaccines and infectious diseases in low and middle-income countries. Most recently Kamel was a Deputy Director at the Bill & Melinda Gates Foundation in the Polio Program, the Regional Immunization Advisor at UNICEF for the Middle East and North Africa and the coordinator of the Decade of Vaccines secretariat at the WHO. He was also the director of the SIVAC Initiative at AMP which provided direct technical assistance to strengthen and establish NITAGs in countries. He also worked at PAHO as a medical officer for IHR and outbreak response and as a medical officer at the French MoH. Kamel is a Medical Doctor with a Public Health Specialty from Paris University. He also earned a Master of Science in Epidemiology from Paris University and a Master of Science, Health policy, planning and financing from London School of Economics and London School of Hygiene and Tropical Medicine.

the French MoH. Kamel is a Medical Doctor with a Public Health Specialty from Paris University. He also earned a Master of Science in Epidemiology from Paris University and a Master of Science, Health policy, planning and financing from London School of Economics and London School of Hygiene and Tropical Medicine.

**Melanie Saville, MB, BS**, joined the Coalition for Epidemic Preparedness Innovations (CEPI) in November 2017. She is the Executive Director of Vaccine Research & Development, and leads the technical teams supporting the vaccine development and enabling science projects funded by CEPI and is the R&D and Manufacturing workstream leader for COVAX. Melanie is a physician specialized in virology with 20 yrs of experience in the development and licensure of vaccines for the developed and developing world. Over the years, she has contributed to the development and licensure of several vaccines for seasonal and pandemic influenza, pediatric combinations, Rabies, Japanese Encephalitis and Dengue vaccine in Europe, US and the international area. She is currently a Board member of the International Vaccine Institute (IVI). Melanie obtained her medical degree from University College, London in 1993. She also obtained a Bachelor of Science in Molecular Biology from University College, London and a master's in medical Virology from Imperial College, London. In the vaccine industry, Melanie has held positions of increasing responsibility in research and development working for Wyeth, Sanofi Pasteur and Janssen vaccines and prevention.



**Dr Naveen Thacker** is the Director of Deep Children Hospital & Research Centre at Gandhidham-Kutch, Gujarat, India and an Adjunct Professor of Pediatrics at Pramukhswami Medical College, Karamsad Anand, Gujarat, India. He is the President-Elect of the International Pediatric Association (IPA) for the year 2021-2023 and Secretary of Child Health Foundation. He is a former President of Asia Pacific Pediatric Association (APPA) for the year 2016-18 and the National President of Indian Academy of Pediatrics (IAP) for the year 2007. He is currently a member of the Advance Course of Vaccinology (ADVAC) Scientific Committee, France and the Steering Committee of the International Collaboration on Advanced Vaccinology training (ICAVT). Also, he is a member of the Covid-19 Vaccine Immunization Task Force of Gujarat

Also, he is a member of the Covid-19 Vaccine Immunization Task Force of Gujarat

Government and India Expert Advisory Group on Measles and Rubella (IEAG- MR) of Ministry of Health and Family Welfare, Government of India. He completed ADVAC Training in Annecy, France in Pasteur Merieux Institute in 2007. He served as a course director for CHF INCLIN ADVAC 2011, 2016, EVAC 2017. He was faculty at CHF-INCLIN ADVAC, CMC Vellore INDVAC, IVI Korea. His current interest is in the area of Vaccine Hesitancy and is leading the IPA Vaccine Trust Project. He has over 50 publications on vaccines and immunization in peer indexed journals. His social media reach includes 78k+ followers on Twitter. He is listed amongst the top influencer for the fight against Polio released by UNICEF on World Polio Day 2017 and has been awarded some prestigious awards i.e., Outstanding Asian Pediatrician Award 2012, Rotary International Regional Award for Polio-free World 2010.



**Dr Rodolfo Villena** is a Pediatric Infectious Diseases Specialist and Associate Professor in the Faculty of Medicine at the University of Chile. Dr Villena's research focus includes pediatric vaccines, epidemiology and invasive diseases. He has participated as Principal Investigator and/or Sub-Investigator in various phase I, II, III and IV studies. He has also published in indexed journals and book chapters on topics including pediatric vaccines, epidemiology, invasive diseases, and antimicrobial PK/PD in pediatric. Dr Villena is an active member of the Chilean Society of Infectious Diseases and the Latinoamerican Society of Pediatric Infectious Diseases. He is also a Director of the International Advanced Course of Vaccines in the University of Chile. In addition, he has actively served as part of the Advisory Committee of Immunization for the Chilean Society of Infectious Diseases and the Advisory Committee of Pharmacovigilance of Vaccines in the Public Health Institute for the Chilean Ministry of Health.

**Dr Adesola Yinka-Ogunleye** is an Epidemiologist and global health professional with over 15 years' experience in national and international public health roles. Her interest is in disease surveillance and public health response to infectious diseases. At the Nigeria Centres for Disease Control, Adesola supported the Nigeria surveillance and response system, including leading the adaptation and review of the Nigeria Integrated Disease Surveillance and Response (IDSR) guidelines in 2019/2020. She worked extensively investigating and responding to epidemics and complex multi-sectoral public health events including cholera, Lassa Fever, meningitis, polio, yellow fever, and mpox. Adesola led Nigeria's response and control of cholera between 2016 and 2018 and the response to mpox resurgence between 2017 and 2020. Adesola is well experienced in implementation of vaccination as a public health intervention during infectious diseases outbreaks. She is a member of the WHO SAGE working group on Smallpox/monkeypox vaccine as well as mpox Clinical Management and Infection Prevention and Control working groups. She was a member of the Nigeria Polio Emergency Operations Centre. She holds BDS and MPH (Field Epidemiology) degrees from the University of Ibadan, Nigeria and, in-view, a PhD in Infectious Diseases Epidemiology at the Institute of Global Health, University College London, UK. She is a 2018/19 African Public Health Leaders Fellow, Chatham House, UK. She is well published.

